Modality
mAb
MOA
CAR-T BCMA
Target
KRASG12C
Pathway
Incretin
PTSD
Development Pipeline
Preclinical
~Jun 2014
→ ~Sep 2015
Phase 1
~Dec 2015
→ ~Mar 2017
Phase 2
Jun 2017
→ Mar 2027
Phase 2Current
NCT07461701
795 pts·PTSD
2017-06→2027-03·Completed
NCT07278462
1,388 pts·PTSD
2020-10→2025-12·Not yet recruiting
2,183 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-12-064mo agoPh3 Readout· PTSD
2027-03-2312mo awayPh3 Readout· PTSD
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P2/3
Complet…
P2/3
Not yet…
Catalysts
Ph3 Readout
2025-12-06 · 4mo ago
PTSD
Ph3 Readout
2027-03-23 · 12mo away
PTSD
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07461701 | Phase 2/3 | PTSD | Completed | 795 | MRD |
| NCT07278462 | Phase 2/3 | PTSD | Not yet recr... | 1388 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| JNJ-179 | Johnson & Johnson | Approved | KRASG12C | |
| BMY-4586 | Bristol-Myers Squibb | Preclinical | KRASG12C | |
| Doxarapivir | Bristol-Myers Squibb | Phase 3 | KRASG12C | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| AMG-4531 | Amgen | Phase 2/3 | KRASG12C | |
| VRT-1891 | Vertex Pharma | Phase 1 | KRASG12C | |
| Pemitapinarof | BeiGene | Approved | KRASG12C | |
| ITC-6153 | Intra-Cellular | Phase 3 | KRASG12C |